Section 1: Executive Synthesis and Foundational Concepts
1.1. Executive Summary: Establishing the Performance Protocol
The comprehensive systematic review and meta-analysis concerning the effects of acute caffeine ingestion on Repeated Sprint Ability (RSA) provide robust, high-certainty evidence that caffeine functions as a highly effective ergogenic aid for high-intensity intermittent performance. The overall conclusion, drawn from pooling data across thirteen high-quality studies, confirms a statistically significant enhancement in the capacity of athletes to maintain maximal power during repeated efforts.
The findings translate directly into a specific, evidence-based performance optimization protocol. Maximal benefit is achieved through the acute administration of a dose set at or above 6 mg/kg Body Weight (BW), ingested approximately 60 minutes before the initiation of the exercise or competition event. While this high dose maximizes performance gains, analysis of existing literature emphasizes that increasing the dose further, for instance, to 9 mg/kg BW, does not yield greater ergogenic effects due to a physiological ceiling, yet it substantially increases the likelihood of experiencing dose-dependent adverse effects such as anxiety, gastrointestinal discomfort, or insomnia. Therefore, 6 mg/kg BW represents the optimal therapeutic window for high-level athletes, balancing performance maximization with safety.
1.2. Defining the Performance Metric: Repeated Sprint Ability (RSA)
Repeated Sprint Ability (RSA) is a crucial physiological parameter defined as the capacity of an individual to execute multiple, short-duration, maximal or near-maximal sprints interspersed with minimal recovery intervals. Typical RSA protocols involve sprint durations of approximately 4 to 6 seconds, followed by rest periods ranging from 20 to 60 seconds.
This capacity is fundamentally important for success in modern high-intensity intermittent team sports, including basketball, football (soccer), rugby, and handball. In these sports, performance is not determined merely by peak speed or stamina, but by the ability to repeatedly execute explosive actions—such as making a rapid defensive recovery, chasing a breakaway, or initiating a fast offensive play—despite the progressive accumulation of metabolic fatigue. The efficacy of caffeine in this context targets the specific metabolic pathway governing these actions. RSA depends primarily on the immediate, anaerobic Adenosine Triphosphate-Creatine Phosphate (ATP-CP) energy system. By influencing neuromuscular and central nervous system function, caffeine helps delay the functional decline of this system, thereby preserving the athlete’s ability to produce maximal force output over successive sprints.
1.3. Caffeine as an Ergogenic Aid: Status and Mechanism Overview
Caffeine is recognized globally as the most widely used legal psychoactive substance and is designated as a potent ergogenic aid in the field of sports science. Its use gained full legitimacy in elite sports following its removal from the World Anti-Doping Agency’s (WADA) list of prohibited substances in 2004.
Caffeine’s ability to augment athletic performance stems from its dual action on the nervous system. Primarily, it functions as a non-selective adenosine receptor antagonist and, consequently, acts as a central nervous system (CNS) stimulant. Upon rapid absorption, caffeine initiates diverse physiological effects critical for performance enhancement, including heightened alertness, the reduction of fatigue perception, and the enhancement of lipolysis (fat breakdown). The performance benefits for high-intensity, anaerobic exercise specifically involve reduced pain perception, improved neural drive, and enhanced muscle contractility. These mechanisms collectively allow the athlete to recruit muscle fibers more effectively and sustain maximal effort for longer periods during repeated efforts.
Section 2: Decoding the Methodology: The Standard of Scientific Evidence
2.1. The Systematic Review and Meta-Analysis Framework
The present investigation utilizes a systematic review and meta-analysis, which represents the highest echelon in the hierarchy of evidence-based practice. This methodological approach ensures that conclusions are not based on isolated findings but on a comprehensive synthesis of all available, high-quality empirical data.
The systematic review process required a comprehensive search across five major databases (PubMed, EBSCO, Cochrane Library, Web of science, and Scopus) up to September 2025. The inclusion criteria were strictly established using the PICO (Population, Intervention, Comparison, Outcome) principle, focusing specifically on human participants, acute caffeine intervention (not long-term use), comparison against a placebo control group, and the outcome of Peak Power Output (PPO). This rigor led to the inclusion of 13 studies that met all quality and relevance standards. The methodology was further validated by adherence to the stringent PRISMA guidelines and prospective registration with the PROSPERO database (registration number CRD420251150247), confirming the scientific integrity of the process.
2.2. Quality Assessment and Reliability
The methodological quality of all included studies was assessed using two validated tools: the Cochrane risk of bias tool and the Physiotherapy Evidence Database (PEDro) scale. The assessment confirmed that the vast majority of studies demonstrated a low risk of bias across domains such as selection, performance, detection, attrition, and reporting. Notably, all 13 included studies were classified as having excellent quality based on the PEDro scale. Furthermore, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach rated the overall certainty of the evidence as high, indicating strong confidence that subsequent research is unlikely to alter the core conclusions regarding caffeine’s effectiveness on RSA.
2.3. Translating Key Scientific Jargon: Quantifying the Effect
The statistical components of the meta-analysis provide a precise quantification of the performance benefit, essential for translational understanding.
Peak Power Output (PPO)
Peak Power Output (PPO) served as the primary endpoint for the meta-analysis. PPO represents the maximal mechanical power generated instantaneously during a sprint, typically measured in Watts during cycling protocols. A significant improvement in PPO across repeated efforts is the objective indicator that caffeine effectively delays fatigue and maintains the athlete’s explosive capacity. For running-based tests, PPO was estimated by converting the fastest sprint time using the validated equation:
Power output=time (s)3body mass (kg)×distance (m)2
.
Weighted Mean Difference (WMD) and Confidence Interval (CI)
The overall effect of caffeine was quantified using the Weighted Mean Difference (WMD), which statistically pools the performance difference observed between the caffeine and placebo conditions across all studies. The resulting WMD for the overall analysis was 5.28. This figure represents the average absolute increase in PPO attributable to caffeine ingestion. Crucially, the 95% Confidence Interval (CI) for this overall effect was 2.49 to 8.07. Since the lower bound of this interval is well above zero, the null hypothesis (that caffeine has no effect) is soundly rejected, confirming the statistical significance and reliability of the performance enhancement (p=0.0002).
Assessment of Heterogeneity (I2)
The I2 statistic is used to assess heterogeneity, measuring the percentage of variation across study results that is not due to chance. The overall meta-analysis reported an extremely low heterogeneity of I2=7%. This low value is highly important because it demonstrates that the individual studies included in the analysis reported remarkably consistent findings regarding caffeine’s effect on RSA. This consistency substantially increases confidence in the overall calculated WMD of 5.28, reinforcing that the observed effect is a pervasive biological phenomenon rather than an outcome contingent on unique laboratory conditions or participant characteristics within a single study.
Section 3: The Mechanism of Action: Why Caffeine Translates to Power Output
3.1. Antagonism of Adenosine Receptors (A1 and A2A)
The foundation of caffeine’s ergogenic action is its primary role as a non-selective adenosine receptor antagonist. Adenosine is an endogenous neuromodulator that accumulates in the brain and peripheral tissues during periods of high metabolic activity, such as intense exercise, stress, or extended wakefulness. Its biological function is to signal fatigue and promote reduced neural activity and drowsiness by binding to specific receptors, principally A1 and A2A receptors.
Caffeine, being molecularly similar to adenosine, acts as a competitive antagonist by physically binding to these A1 and A2A receptors. This molecular blockade prevents adenosine from exerting its inhibitory effects. By chemically overriding this “fatigue switch,” caffeine delays the central nervous system’s perception of exhaustion and pain. This central effect is paramount for RSA performance, as maintaining maximal power output during repeated sprints requires continuous, high levels of volitional effort, which caffeine ingestion facilitates by enhancing subjective alertness. This mechanism explains the effectiveness of caffeine in modifying brain functions and improving cognitive markers related to effort perception.
3.2. Enhanced Neuromuscular Function and Peripheral Drive
Beyond its central effects, caffeine also acts as a CNS stimulant, leading to improved peripheral physiological responses. The antagonism of adenosine receptors contributes to an increased release of neurotransmitters, which in turn enhances the neural drive from the brain to the working muscles.
Furthermore, caffeine directly affects the machinery of the muscle fibres themselves, facilitating enhanced muscle contractility. This is believed to occur through modulation of intracellular calcium handling within the sarcoplasmic reticulum. Improved calcium release and reuptake kinetics mean that muscle cells can generate force faster and more powerfully with each neural impulse. This translates directly into the improved PPO observed during the sprint efforts of RSA protocols.
3.3. Pharmacokinetic Consistency and Timing
The consistent recommendation for administering caffeine 60 minutes before exercise is dictated by pharmacokinetics, the study of how the body interacts with the substance. Caffeine is rapidly absorbed following ingestion, typically reaching its peak plasma concentration approximately 60 minutes post-ingestion in healthy adults. The standardization of this timing across all studies ensured that the maximum beneficial concentration of caffeine—and thus its peak effect on both CNS stimulation and muscle contractility—coincided precisely with the required maximal performance output during the RSA testing. This methodological consistency is a key factor enabling the high reliability and low heterogeneity reported in the pooled results.
Section 4: Comprehensive Findings: Quantifying Caffeine’s Effects on RSA
4.1. Overall Magnitude of Effect
The pooled analysis, encompassing data from 360 participants across 13 studies, demonstrated unequivocally that acute caffeine ingestion produces a statistically significant ergogenic effect on RSA. The primary finding showed that caffeine significantly enhanced RSA Peak Power Output (PPO) compared with a placebo.
The magnitude of this generalized performance gain was quantified by a Weighted Mean Difference (WMD) of 5.28, with a 95% Confidence Interval (CI) ranging from 2.49 to 8.07. The statistical certainty of this effect was extremely high (p=0.0002). This outcome reinforces caffeine’s critical role as an effective strategy for optimizing high-intensity intermittent performance by producing a reliable and quantifiable gain in maximal power output throughout the sequence of repeated sprints.
4.2. Subgroup Analysis: The Critical Dosage Threshold
The analysis explicitly stratified data based on caffeine dosage relative to body weight, definitively establishing a dose-response relationship. This stratification confirmed a clear minimum effective threshold required to elicit a statistically significant performance benefit.
High Dose (≥6 mg/kg BW)
Doses of caffeine administered at or above 6 mg/kg BW produced the strongest and most significant ergogenic benefits. The WMD for this high-dose subgroup was 6.67, with a CI of 3.32 to 10.02, confirming a highly reliable and substantial performance improvement (p<0.0001). This level of dosing is deemed necessary for the average athlete to antagonize enough adenosine receptors to meaningfully impact central drive and neuromuscular function.
Low Dose (<6 mg/kg BW)
In contrast, when caffeine was administered at low doses (less than 6 mg/kg BW), the pooled analysis found no statistically significant improvement in RSA. The WMD for the low-dose subgroup was 2.16, but the 95% CI (-2.87 to 7.19) crossed zero, indicating that the true effect could potentially be negligible or even negative, and the result was statistically non-significant (p=0.40).
This observation implies that for the majority of the athletic population, a critical plasma concentration must be reached to effectively influence performance. It is important to acknowledge, however, an exception for individuals classified as low habitual caffeine consumers (e.g., intake <60 mg/day). These individuals, due to heightened sensitivity, may achieve threshold benefits even at lower doses, whereas high habitual consumers require the full ≥6 mg/kg BW dose to overcome acquired physiological tolerance.
4.3. Subgroup Analysis: Influence of Exercise Modality
The meta-analysis examined performance outcomes across the two most common RSA assessment formats: cycling and running. Significant improvements were observed in both modalities, confirming caffeine’s generalized efficacy regardless of the specific movement pattern.
Cycling Protocols
Cycling-based RSA protocols showed the largest numerical magnitude of enhancement, with a WMD of 8.77 (CI 1.98 to 15.56). This effect was statistically significant (p=0.01).
Running Protocols
Running-based RSA protocols also exhibited a statistically significant enhancement, with a WMD of 4.56 (CI 1.58 to 7.55) (p=0.003).
The observation that the cycling WMD (8.77) was nearly double that of the running WMD (4.56) is critical for translation. This numerical difference is likely not due to a superior biological effect of caffeine during cycling. Rather, cycling RSA tests impose mechanically fixed parameters, enabling highly precise PPO measurement and minimizing confounding variables (e.g., technique breakdown, balance, and energy expenditure on stabilization) inherent in running. Consequently, the larger WMD in cycling may represent a measurement artefact that captures the athlete’s maximal isolated physiological capacity under optimized laboratory conditions. The running protocols, despite the smaller WMD, possess higher ecological validity for athletes in field sports, as they replicate the complex neuromuscular demands required in competition. For practical application, the significant effect seen in running protocols (p=0.003) is highly relevant for team sport coaches.
4.4. Subgroup Analysis: Consistency Across Participant Sex
The analysis confirmed that acute caffeine ingestion significantly enhanced RSA performance in both male and female participants.
Findings by Sex
- Male Participants: Demonstrated a highly pronounced ergogenic effect, resulting in a WMD of 13.11 (CI 5.63 to 20.59), with strong statistical significance (p=0.0006).
- Female Participants: Also showed significant performance improvements, with a WMD of 4.03 (CI 1.10 to 6.97), and strong statistical significance (p=0.007).
Physiological Nuance and Metabolic Differences
Despite the substantial numerical difference in the magnitude of the WMD between males (13.11) and females (4.03), the overall pooled analysis concluded that there was no statistically significant sex difference. This pooled result, however, obscures an underlying biological mechanism related to metabolism.
Physiological research indicates that females tend to metabolize caffeine more slowly than males. This difference is largely attributed to the influence of estrogen, which acts to inhibit the activity of CYP1A2, the primary hepatic enzyme responsible for caffeine degradation. Slower metabolism in females results in prolonged plasma caffeine concentrations. This prolonged availability may explain observed differences in performance timing, where empirical evidence suggests males often demonstrate higher PPO in the initial sprints of an RSA protocol, while females show superior PPO and greater fatigue mitigation in the final sprints. Therefore, while caffeine is beneficial for both sexes, the precise temporal window of benefit may differ, emphasizing the need for personalized monitoring, especially considering the hormonal status of female athletes.
Table 4: Synthesis of Subgroup Analysis Findings
| Caffeine Effect | Performance Metric | Key Statistical Finding (WMD) | P-Value | Translational Interpretation |
| Overall Effect | RSA Peak Power Output (PPO) | 5.28 (CI: 2.49 to 8.07) | 0.0002 | Highly reliable, generalized performance enhancement. |
| High Dose (≥6 mg/kg BW) | RSA PPO | 6.67 (CI: 3.32 to 10.02) | <0.0001 | Optimal dose identified; required threshold for maximal gain. |
| Low Dose (<6 mg/kg BW) | RSA PPO | 2.16 (CI: -2.87 to 7.19) | 0.40 | Inconsistent and non-significant effect for the general population. |
| Cycling Modality | RSA PPO | 8.77 (CI: 1.98 to 15.56) | 0.01 | Largest numerical WMD, likely representing maximal physiological potential. |
| Running Modality | RSA (Fastest Sprint Time) | 4.56 (CI: 1.58 to 7.55) | 0.003 | Significant and highly applicable benefit for field athletes. |
| Male Participants | RSA PPO | 13.11 (CI: 5.63 to 20.59) | 0.0006 | Highly pronounced effect magnitude; may show early performance peak. |
| Female Participants | RSA PPO | 4.03 (CI: 1.10 to 6.97) | 0.007 | Consistent benefit, may show prolonged effect and later fatigue mitigation. |
Section 5: Practical Translation: Applying the Science to Performance Protocols
5.1. Implementing the Optimal Dosing Strategy
Based on the evidence that the high-dose threshold (≥6 mg/kg BW) confers maximum benefit while avoiding the non-ergogenic risks of unnecessarily high doses, practitioners should calculate the dose precisely. The determination of the exact dose must begin with accurate measurement of the athlete’s body mass.
For instance, an athlete with a body mass of 80 kg requires an acute dose of 80×6=480 mg of caffeine. Since caffeine’s effect is dose-dependent, using pre-measured capsules or accurately weighed powders is the recommended administration method to ensure the precise 6 mg/kg BW target is achieved, mitigating the uncertainty inherent in natural caffeine sources or energy drinks. The timing of 60 minutes pre-exercise is mandatory to ensure peak plasma concentration is achieved at the critical moment of high-intensity activity.
5.2. Personalization and Tolerance Management
The efficacy of the 6 mg/kg BW protocol is significantly modulated by the athlete’s history of caffeine consumption. Individuals with a low habitual intake (typically <60 mg/day) are highly responsive and may experience maximal benefits at doses lower than 6 mg/kg BW. If an athlete with low habitual intake is subjected to the full 6 mg/kg BW dose, they may experience adverse effects without gaining additional performance benefit.
Conversely, high habitual consumers may have developed tolerance, making the full 6 mg/kg BW dose necessary to achieve the desired ergogenic outcome. Therefore, before implementing the maximal evidence-based dose, performance staff must conduct controlled trials during non-critical training sessions to assess individual tolerance and responsiveness, ensuring the protocol is effective and safe for the specific athlete.
5.3. Safety and Risk Mitigation: Identifying the Adverse Effect Threshold
The analysis demonstrates that the risk of adverse effects is low within the recommended 3–6 mg/kg BW range but escalates significantly at higher dosages, such as those approaching 9 mg/kg BW. Doses exceeding the 6 mg/kg BW threshold have been documented to cause increased incidence of symptoms, including anxiety, irritability, and gastrointestinal distress. Since the literature indicates that 9 mg/kg BW offers no proven performance advantage over 6 mg/kg BW (the ceiling effect), maximizing performance must be tempered by prioritizing the athlete’s health and safety. The determination that 6 mg/kg BW is the optimal upper limit is essential for adherence to best practices in sports nutrition.
Section 6: Study Limitations, Caveats, and Future Research Directives
6.1. Methodological Challenges and Need for Standardization
Despite the strength of the meta-analytic findings, several limitations warrant consideration when applying these conclusions.
First, the primary limitation lies in the necessary heterogeneity concerning the athletic capabilities of the participants, including differences in training status and sport-specific demands. These factors inherently modulate the magnitude of the ergogenic response, suggesting that an athlete highly trained for one discipline may respond differently to the standardized caffeine protocol than an athlete from a different sporting background.
Second, the review included studies using different forms of caffeine administration, such as capsules and powder. Although statistically pooled, the subtle differences in the absorption profiles of these forms may contribute marginally to result variability.
6.2. The Ecological Validity Gap
The observation that cycling protocols yielded a numerically larger WMD (8.77) than running protocols (4.56) is a critical translational caveat. As previously discussed, the cycling data may represent maximal physiological capability in an artificial environment. For athletes in field-based sports where movement is complex and requires stability and agility, the running-based results hold superior ecological validity. Therefore, future research must prioritize studies employing sport-specific RSA protocols—such as tests simulating the specific demands of soccer or basketball—to further refine the evidence base and enhance the translational utility of caffeine research in applied sports settings.
6.3. Directives for Future Research
The current analysis establishes the efficacy of caffeine but necessitates further refinement in specific populations.
First, future research must explicitly investigate sex as a moderator, controlling for factors such as the menstrual cycle phase (in females) and genetic markers of metabolic rate to refine timing protocols. Understanding the influence of estrogen on the CYP1A2 enzyme activity will allow practitioners to tailor dosing and timing to account for the temporal shift in performance benefits observed between sexes.
Second, a crucial gap remains in the quantitative analysis of adverse effects. While the study notes that adverse effects increase at 9 mg/kg BW , a systematic analysis is needed to quantify the incidence and severity of symptoms across various effective doses. This step is necessary to fully assess the trade-off between performance gain and physiological risk, ensuring truly holistic safety guidelines.
6.4. Final Conclusions
The systematic review and meta-analysis provide robust, high-certainty evidence that acute caffeine ingestion significantly enhances RSA, an essential capacity for intermittent high-intensity sports. This effect is consistent across both male and female participants and is highly significant in both cycling and running exercise modalities. The key actionable finding for performance staff is the optimal protocol: acute ingestion of ≥6 mg/kg BW, administered 60 minutes pre-exercise, which is confirmed as the effective threshold for maximizing power output and minimizing fatigue during repeated sprints. Adherence to this evidence-based strategy reinforces caffeine’s status as a cornerstone supplement for optimizing athletic performance.